Want to learn more about coronavirus vaccine research and new treatments for COVID-19? Join this webinar to hear about current research into these areas at Imperial College London.
Imperial College Academic Health Science Centre (AHSC) is working at the forefront of research and patient care during the COVID-19 pandemic. In the first of our COVID-19 webinar series, two experts will talk about their work into reducing the impacts of this infection through the development of a new vaccine and other therapeutic approaches.
They have been testing an RNA vaccine candidate in animals since early February.
When injected, the self-amplifying RNA vaccine will deliver genetic instructions to muscle cells to make the ‘spike’ protein on the surface of the coronavirus. The hope is that this will provoke an immune response and create immunity to COVID-19.
Early findings have shown that animals given the vaccine are able to produce neutralising antibodies against the novel coronavirus SARS-CoV-2, which causes COVID-19.
The team have received more than £40 million in funding to launch phase three clinical trials of their promising new vaccine. Their vaccine will begin human trials in June.
Professor Anthony Gordon, Chair in Anaesthesia and Critical Care at Imperial College London and a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust, is leading a trial to investigate whether convalescent plasma transfusions and other treatments improve the speed of recovery and chances of survival for patients with COVID-19.
Convalescent plasma is plasma from the blood of someone who has recovered from a virus. The plasma may contain antibodies that their immune system has produced in fighting the virus - in this case, SARS-CoV-2 - which can then be transfused into infected patients whose immune systems are struggling to fight the infection.
Patients from 120 hospitals in the UK, including Imperial College Healthcare NHS Trust, are being treated with convalescent plasma as part of the REMAP-CAP trial.
COVID-19 is a new disease caused by a novel virus. Many new treatments have been proposed to tackle the multiple symptoms that seriously ill patients experience. Only through randomised controlled trials will we learn their true efficacy and safety. REMAP-CAP is an international platform trial that has been designed specifically to adapt and provide these answers.
Wednesday 17 June 2020
Online event - you will receive a link to join the online event after registering via Eventbrite